ELV (Elevance Health, Inc.) — AI Stock Analysis & Recommendation

Research of September 24, 2026 · Healthcare / Hospital & Medical Service Plans

TradeFlare's AI research teams rate ELV a BUY. The latest price is $425.27.

The research plan

• Entry: $398.25
• Target: $422.14
• Stop: $358.43
• Time horizon: weeks

The fundamental and sentiment tailwinds suggest a medium-term upward trend, while the technical setup indicates an imminent bounce.

Why

The fundamental and sentiment tailwinds suggest a medium-term upward trend, while the technical setup indicates an imminent bounce. Catalysts to watch: Strong fundamental valuation and competitive moat driven by BCBS licenses; Strategic transformation into an integrated 'whole-health' platform; Positive analyst sentiment and institutional ownership. Key risks: Sector-specific regulatory risks; Potential for data security and privacy breaches; Headwinds from rising medical costs and unspecified 2027 issues.

What could push ELV higher

• Strong fundamental valuation and competitive moat driven by BCBS licenses.
• Strategic transformation into an integrated 'whole-health' platform.
• Positive analyst sentiment and institutional ownership.

Key risks for ELV

• Sector-specific regulatory risks.
• Potential for data security and privacy breaches.
• Headwinds from rising medical costs and unspecified 2027 issues.

What each AI research team found

Fundamental team: Bullish · valuation: undervalued

Elevance Health is fundamentally undervalued based on its attractive valuation multiples and strong competitive advantages, particularly its exclusive BCBS licenses and integrated Carelon platform. While recent earnings have dipped, management's reaffirmed growth guidance and overwhelming 'buy' analyst consensus suggest a recovery and significant upside potential, making it a compelling investment.

• Elevance Health (ELV) exhibits attractive valuation multiples (P/E, EV/EBITDA) significantly below industry and peer averages, suggesting undervaluation.
• Strong competitive moat is underpinned by exclusive Blue Cross Blue Shield (BCBS) licenses, high barriers to entry, and significant scale.
• Strategic transformation into an integrated 'whole-health' platform with Carelon services and AI investments positions for future growth.

Technical team: Neutral

The technical analysis indicates a neutral stance for ELV, with price consolidating near resistance and lacking strong conviction from volume or momentum indicators. While moving averages suggest a slight bearish bias, their convergence and the current sideways action warrant caution, making a short-term pullback to $395.00 a plausible scenario.

• Price is consolidating between support ($388.35) and resistance ($401.09), with moving averages suggesting a slight bearish short-to-medium term trend, but convergence indicates potential for a shift.
• Below-average volume over recent weeks and no significant accumulation/distribution spikes suggest a lack of conviction in the current sideways price action.
• Momentum indicators are neutral to slightly bearish, with RSI near 50 and MACD/Stochastic showing weakening downward momentum, but no clear divergences.

Sentiment team: Bullish

Elevance Health exhibits a predominantly positive sentiment, supported by strong Q2 results, reaffirmed guidance, and a consensus 'Buy' rating from analysts. While concerns regarding future headwinds and rising medical costs exist, the overall outlook is bolstered by perceived undervaluation and positive industry developments, suggesting an improving sentiment momentum.

• Neutral sentiment driven by reaffirmed guidance and strong Q2, but tempered by future headwinds and rising medical costs. (Score: 0.062)
• Cautiously optimistic retail sentiment due to reaffirmed guidance, positive industry trends, and perceived undervaluation, despite policy and cost concerns. (Score: 0.15)
• Positive sentiment with a consensus 'Moderate Buy' or 'Buy' rating, significant upside potential, and strong institutional backing, despite a few 'Hold' ratings. (Consensus: Positive)

Risk team: High

Elevance Health presents a high-risk profile driven by significant regulatory dependence, substantial data security risks, and a history of deep drawdowns and elevated volatility. The high days to cover also adds to the potential for sharp price movements. Given these factors, a small position size with a tight stop-loss is recommended to manage the considerable downside risk.

• Sector-Specific Regulatory Risk: Elevance Health operates in a highly regulated sector, making it susceptible to significant impacts from changes in government policies, reimbursement rates, and healthcare regulations.
• Data Security and Privacy Breaches: Handling sensitive personal health information exposes the company to substantial operational and reputational risk from cyberattacks and data breaches.
• Deep 1-Year Drawdown: The stock has experienced a significant drawdown of -51.15% over the past year, indicating substantial historical price depreciation and potential for further downside.

ELV at a glance

Market value	$85.6B
Price / earnings	17.4
Revenue growth (year over year)	6.3%
Profit margin	2.5%
Debt / equity	0.69

Every AI call on ELV since July 20, 2026, and what happened next (5 calls) →

Research of September 24, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.